ReiThera vs Rose BioSolutions: CDMO Comparison
How does ReiThera compare to Rose BioSolutions for AAV manufacturing?
Side-by-side comparison of ReiThera and Rose BioSolutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- ReiThera holds 4 active EMA GMP certificates; Rose BioSolutions does not appear in EudraGMDP.
On a 13-modality CDMO landscape, both ReiThera and Rose BioSolutions qualify as AAV manufacturers; ReiThera carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both ReiThera and Rose BioSolutions qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: ReiThera vs Rose BioSolutions
How does ReiThera compare to Rose BioSolutions for AAV manufacturing?
On CDMO Signal's composite Signal Score, ReiThera is 71/100 and Rose BioSolutions is 63/100; European coverage is 4 active EMA+MHRA certificates for ReiThera vs 0 for Rose BioSolutions. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
How do ReiThera and Rose BioSolutions compare on European GMP coverage?
ReiThera holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Rose BioSolutions holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — ReiThera or Rose BioSolutions?
ReiThera is matched to 1 ClinicalTrials.gov record as a manufacturing partner; Rose BioSolutions is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — ReiThera or Rose BioSolutions?
Both ReiThera and Rose BioSolutions are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
ReiThera carries a Signal Score of 71/100 and Rose BioSolutions carries 63/100 — a small lead for ReiThera. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →